Re­gen­eron, GSK see mas­sive spike in Covid-19 mAb de­mand as US de­bates buy­ing more

The Delta vari­ant is busy dri­ving up new Covid-19 cas­es na­tion­wide, ac­cel­er­at­ing de­mand for mon­o­clon­al an­ti­body treat­ments from Re­gen­eron and Glax­o­SmithK­line, which can re­duce hos­pi­tal­iza­tions …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.